# Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations

> **NCT02971839** · PHASE2 · TERMINATED · sponsor: **Vertex Pharmaceuticals Incorporated** · enrollment: 11 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** VX-561
- **DRUG:** Placebo
- **DRUG:** IVA

## Key facts

- **NCT ID:** NCT02971839
- **Lead sponsor:** Vertex Pharmaceuticals Incorporated
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-12
- **Primary completion:** 2017-08
- **Final completion:** 2017-08
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Decision by Sponsor.
- **Last updated:** 2020-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02971839

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02971839, "Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT02971839. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*